Endocrine Abstracts

Introduction: The prevalence of B-type Raf kinase (BRAFV600E) mutation in PTC has been observed in 30% to over 80%, and it seems that the mutation occurred in the early stage of thyroid carcinoma progression which precedes histological change. Based on previous reports, high body mass index (BMI) is considered a thyroid cancer risk. However, it is unclear whether high BMI has a certain association with the BRAFV600E mutational status. We assess whether high BMI is associated w...

Background: Telomerase reverse transcriptase (TERT) promoter mutation is a poor prognostic factor in differentiated thyroid carcinoma(DTC). It is thought to play a role in the transformation process to undifferentiated thyroid carcinoma(UTC), but its role as a prognostic factor in UTC is unclear. Therefore, in this study, we investigated whether the TERT promoter mutation acts as as an independent poor prognostic factor in UTC.Methods: Among patients dia...

Background: Delayed thyroid-stimulating hormone (TSH) recovery during treatment of Graves’ disease is caused by long-term excessive thyroid hormone, which results in down-regulation of pituitary thyrotropic cells. However, it is unknown whether delayed TSH recovery exists after levothyroxine (LT4) dose adjustment in patients with differentiated thyroid cancer (DTC) who are taking a suppressive dose of LT4.Methods: We retrospectively reviewed 97 DTC ...

Objectives: 18F-choline PET/CT is a recently introduced imaging modality to localize hyperfunctioning parathyroid glands in patient with hyperparathyroidism. But there has been no study according the diagnostic power of 18F-choline PET/CT in Korea so far owing to its limited distribution. Therefore, we evaluated the diagnostic performance of 18F-choline PET/CT in detection of hyperfunctioning parathyroid gland in patients with primary hyperpara...